These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 7504849

  • 1. Comparative analysis of fluctuation of serum tumor markers in advanced cancer of prostate.
    Maatman TJ.
    Urology; 1993 Dec; 42(6):672-6. PubMed ID: 7504849
    [Abstract] [Full Text] [Related]

  • 2. The role of prostate specific antigen as a tumor marker in men with advanced adenocarcinoma of the prostate.
    Maatman TJ.
    J Urol; 1989 Jun; 141(6):1378-80. PubMed ID: 2470927
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The role of serum prostatic acid phosphatase as a tumor marker in men with advanced adenocarcinoma of the prostate.
    Maatman TJ, Gupta MK, Montie JE.
    J Urol; 1984 Jul; 132(1):58-60. PubMed ID: 6726962
    [Abstract] [Full Text] [Related]

  • 5. Advanced prostate cancer follow-up with prostate-specific antigen, prostatic acid phosphatase, osteocalcin and bone isoenzyme of alkaline phosphatase.
    Curatolo C, Ludovico GM, Correale M, Pagliarulo A, Abbate I, Cirrillo Marucco E, Barletta A.
    Eur Urol; 1992 Jul; 21 Suppl 1():105-7. PubMed ID: 1385127
    [Abstract] [Full Text] [Related]

  • 6. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.
    Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N.
    J Urol; 1989 May; 141(5):1076-83. PubMed ID: 2468795
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
    Tarle M.
    Anticancer Res; 1993 May; 13(3):769-77. PubMed ID: 7686362
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Use of serum markers in the diagnosis and management of laryngeal cancer.
    Mevio E, Benazzo M, Galioto P, Spriano P, Pizzala R.
    Clin Otolaryngol Allied Sci; 1991 Feb; 16(1):90-2. PubMed ID: 2032368
    [Abstract] [Full Text] [Related]

  • 13. Tissue polypeptide antigen (TPA) as a prognostic aid in human prostatic carcinoma.
    Lewenhaupt A, Ekman P, Eneroth P, Nilsson B, Nordström L.
    Prostate; 1985 Feb; 6(3):285-91. PubMed ID: 3991370
    [Abstract] [Full Text] [Related]

  • 14. Critical assessment of prostate cancer staging.
    Graham SD.
    Cancer; 1992 Jul 01; 70(1 Suppl):269-74. PubMed ID: 1376195
    [Abstract] [Full Text] [Related]

  • 15. Serum TPS, PSA, and PAP values in relapsing stage D2 adenocarcinoma of the prostate.
    Kraljić I, Kovacić K, Tarle M.
    Urol Res; 1994 Jul 01; 22(5):329-32. PubMed ID: 7533445
    [Abstract] [Full Text] [Related]

  • 16. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients.
    Stamey TA, Kabalin JN, Ferrari M.
    J Urol; 1989 May 01; 141(5):1084-7. PubMed ID: 2468796
    [Abstract] [Full Text] [Related]

  • 17. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate. Ohio State University experience.
    Drago JR, Badalament RA, Wientjes MG, Smith JJ, Nesbitt JA, York JP, Ashton JJ, Neff JC.
    Urology; 1989 Oct 01; 34(4):187-92. PubMed ID: 2477931
    [Abstract] [Full Text] [Related]

  • 18. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
    Filella X, Molina R, Jo J, Umbert B, Bedini JL, Ballesta AM.
    Tumour Biol; 1990 Oct 01; 11(6):289-94. PubMed ID: 1700860
    [Abstract] [Full Text] [Related]

  • 19. Prospective investigation of tumor markers and risk assessment in early cancer screening.
    Kobayashi T, Kawakubo T.
    Cancer; 1994 Apr 01; 73(7):1946-53. PubMed ID: 8137222
    [Abstract] [Full Text] [Related]

  • 20. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.
    Akimoto S, Inomiya H, Akakura K, Shimazaki J, Ito H.
    Jpn J Clin Oncol; 1997 Aug 01; 27(4):258-62. PubMed ID: 9379515
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.